Abstract
To the Editor: Coronavirus disease 2019 (COVID-19) took the world by surprise. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family of coronaviruses.
1
Mental health personnel focus on mitigating psychological morbidities caused by the distress induced by this pandemic. There are psychiatric adversities caused by the virus, immunologic host responses, and some treatment modalities.
1,2 Following previous coronavirus outbreaks, postviral sequelae were noted, with anxiety, psychoses, and a variety of mood disorders.
3
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
1. Lai C, Shih T, Ko W, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
2. Lyons D, Frampton M, Naqvi S, et al. Fallout from the Covid-19 pandemic—should we prepare for a tsunami of post viral depression? Ir J Psychol Med 2020:1–10.
3. Honigsbaum M. “An inexpressible dread”: psychoses of influenza at fin-de-siècle. Lancet 2013;381:988–989.
4. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 2020;87:34–39.
5. Brietzke E, Magee T, Freire R, et al. Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic. Brain Behav Immun Health 2020;5:100076.
6. Chu H, Chan J, Yuen T, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 2020;1:E14–E23.
7. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:1–9.
8. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7:611–627.
9. Okusaga O, Yolken RH, Langenberg P, et al. Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. J Affect Disord 2011;130:220–225.
10. Ochsendorf FR, Runne U. Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs. Hautarzt 1991;42:140–146.
11. Severance EG, Dickerson FB, Viscidi RP, et al. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull 2011;37:101–107.
12. HsuWY, Chiu NY, Huang SS. Hydroxychloroquineinduced acute psychosis in a systemic lupus erythematosus female. Acta Neuropsychiatr 2011;23:318–319.
13. Tsai L-K, Hsieh S-T, Chao C-C, et al. Neuromuscular disorders in severe acute respiratory syndrome.
Arch Neurol 2014;61:1669–1673.
14. Chang C-H, Chang Y-C, Tzang R-F. Childhood psychosis after H1N1 influenza. J Neuropsychiatry Clin Neurosci 2015;27:e87–e89.
15. Lee AM, Wong JGWS, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry 2007;52:233–240.
